nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—CYP2C19—Methimazole—Graves' disease	0.134	0.25	CbGbCtD
Imatinib—CYP1A2—Methimazole—Graves' disease	0.124	0.231	CbGbCtD
Imatinib—CYP2C9—Methimazole—Graves' disease	0.111	0.208	CbGbCtD
Imatinib—CYP2D6—Methimazole—Graves' disease	0.102	0.19	CbGbCtD
Imatinib—CYP3A4—Methimazole—Graves' disease	0.0647	0.121	CbGbCtD
Imatinib—Pigmentation skin—Methimazole—Graves' disease	0.0323	0.121	CcSEcCtD
Imatinib—Pigmentation skin—Propylthiouracil—Graves' disease	0.0274	0.103	CcSEcCtD
Imatinib—Pigmentation disorder—Methimazole—Graves' disease	0.0177	0.0662	CcSEcCtD
Imatinib—Allergic cutaneous angiitis—Propylthiouracil—Graves' disease	0.0158	0.0591	CcSEcCtD
Imatinib—Pigmentation disorder—Propylthiouracil—Graves' disease	0.015	0.0563	CcSEcCtD
Imatinib—Interstitial pneumonia—Propylthiouracil—Graves' disease	0.0104	0.0389	CcSEcCtD
Imatinib—Leukocytoclastic vasculitis—Propylthiouracil—Graves' disease	0.0102	0.0383	CcSEcCtD
Imatinib—Interstitial lung disease—Propylthiouracil—Graves' disease	0.00708	0.0265	CcSEcCtD
Imatinib—ABCA3—eye—Graves' disease	0.00678	0.0465	CbGeAlD
Imatinib—Aplastic anaemia—Methimazole—Graves' disease	0.00553	0.0207	CcSEcCtD
Imatinib—Vasculitis—Propylthiouracil—Graves' disease	0.00514	0.0192	CcSEcCtD
Imatinib—ABCA3—pituitary gland—Graves' disease	0.00503	0.0345	CbGeAlD
Imatinib—Lymphadenopathy—Methimazole—Graves' disease	0.00502	0.0188	CcSEcCtD
Imatinib—ABCA3—adipose tissue—Graves' disease	0.00501	0.0344	CbGeAlD
Imatinib—Aplastic anaemia—Propylthiouracil—Graves' disease	0.00471	0.0176	CcSEcCtD
Imatinib—DDR1—pituitary gland—Graves' disease	0.00464	0.0319	CbGeAlD
Imatinib—DDR1—adipose tissue—Graves' disease	0.00463	0.0317	CbGeAlD
Imatinib—ABCA3—thyroid gland—Graves' disease	0.00434	0.0298	CbGeAlD
Imatinib—Lymphadenopathy—Propylthiouracil—Graves' disease	0.00426	0.016	CcSEcCtD
Imatinib—Hepatic failure—Propylthiouracil—Graves' disease	0.00405	0.0152	CcSEcCtD
Imatinib—DDR1—thyroid gland—Graves' disease	0.004	0.0275	CbGeAlD
Imatinib—Renal failure acute—Propylthiouracil—Graves' disease	0.00394	0.0148	CcSEcCtD
Imatinib—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.00386	0.0144	CcSEcCtD
Imatinib—CA3—connective tissue—Graves' disease	0.00355	0.0244	CbGeAlD
Imatinib—Neuropathy peripheral—Methimazole—Graves' disease	0.00323	0.0121	CcSEcCtD
Imatinib—Jaundice—Methimazole—Graves' disease	0.00321	0.012	CcSEcCtD
Imatinib—Agranulocytosis—Methimazole—Graves' disease	0.00308	0.0115	CcSEcCtD
Imatinib—ABL2—pituitary gland—Graves' disease	0.00303	0.0208	CbGeAlD
Imatinib—ABL2—adipose tissue—Graves' disease	0.00302	0.0207	CbGeAlD
Imatinib—Hepatitis—Methimazole—Graves' disease	0.00296	0.0111	CcSEcCtD
Imatinib—PIP4K2C—pituitary gland—Graves' disease	0.00287	0.0197	CbGeAlD
Imatinib—PIP4K2C—adipose tissue—Graves' disease	0.00285	0.0196	CbGeAlD
Imatinib—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00275	0.0103	CcSEcCtD
Imatinib—CA3—pituitary gland—Graves' disease	0.00274	0.0188	CbGeAlD
Imatinib—Jaundice—Propylthiouracil—Graves' disease	0.00273	0.0102	CcSEcCtD
Imatinib—CA3—adipose tissue—Graves' disease	0.00273	0.0187	CbGeAlD
Imatinib—PDGFRA—connective tissue—Graves' disease	0.00273	0.0187	CbGeAlD
Imatinib—Agranulocytosis—Propylthiouracil—Graves' disease	0.00262	0.0098	CcSEcCtD
Imatinib—Alopecia—Methimazole—Graves' disease	0.00262	0.0098	CcSEcCtD
Imatinib—ABL2—thyroid gland—Graves' disease	0.00261	0.0179	CbGeAlD
Imatinib—CA12—eye—Graves' disease	0.00261	0.0179	CbGeAlD
Imatinib—LCK—adipose tissue—Graves' disease	0.00253	0.0174	CbGeAlD
Imatinib—Haemoglobin—Propylthiouracil—Graves' disease	0.00253	0.00948	CcSEcCtD
Imatinib—Haemorrhage—Propylthiouracil—Graves' disease	0.00252	0.00943	CcSEcCtD
Imatinib—Hepatitis—Propylthiouracil—Graves' disease	0.00252	0.00943	CcSEcCtD
Imatinib—CA12—connective tissue—Graves' disease	0.00252	0.0173	CbGeAlD
Imatinib—CSF1R—eye—Graves' disease	0.00249	0.0171	CbGeAlD
Imatinib—PIP4K2C—thyroid gland—Graves' disease	0.00247	0.017	CbGeAlD
Imatinib—CSF1R—connective tissue—Graves' disease	0.0024	0.0165	CbGeAlD
Imatinib—CA3—thyroid gland—Graves' disease	0.00236	0.0162	CbGeAlD
Imatinib—Vertigo—Methimazole—Graves' disease	0.00232	0.00868	CcSEcCtD
Imatinib—Leukopenia—Methimazole—Graves' disease	0.00231	0.00864	CcSEcCtD
Imatinib—SLC47A1—eye—Graves' disease	0.00227	0.0156	CbGeAlD
Imatinib—Alopecia—Propylthiouracil—Graves' disease	0.00222	0.00833	CcSEcCtD
Imatinib—PDGFRB—eye—Graves' disease	0.00221	0.0152	CbGeAlD
Imatinib—Arthralgia—Methimazole—Graves' disease	0.00219	0.00822	CcSEcCtD
Imatinib—Myalgia—Methimazole—Graves' disease	0.00219	0.00822	CcSEcCtD
Imatinib—LCK—thyroid gland—Graves' disease	0.00219	0.0151	CbGeAlD
Imatinib—KIT—connective tissue—Graves' disease	0.00218	0.015	CbGeAlD
Imatinib—Dysgeusia—Propylthiouracil—Graves' disease	0.00215	0.00804	CcSEcCtD
Imatinib—PDGFRB—connective tissue—Graves' disease	0.00213	0.0146	CbGeAlD
Imatinib—NQO2—pituitary gland—Graves' disease	0.00211	0.0144	CbGeAlD
Imatinib—Oedema—Methimazole—Graves' disease	0.0021	0.00788	CcSEcCtD
Imatinib—NQO2—adipose tissue—Graves' disease	0.0021	0.0144	CbGeAlD
Imatinib—PDGFRA—adipose tissue—Graves' disease	0.00209	0.0144	CbGeAlD
Imatinib—CA1—eye—Graves' disease	0.00207	0.0142	CbGeAlD
Imatinib—Thrombocytopenia—Methimazole—Graves' disease	0.00206	0.00772	CcSEcCtD
Imatinib—ABL1—eye—Graves' disease	0.00197	0.0135	CbGeAlD
Imatinib—Vertigo—Propylthiouracil—Graves' disease	0.00197	0.00738	CcSEcCtD
Imatinib—Leukopenia—Propylthiouracil—Graves' disease	0.00196	0.00735	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00192	0.00718	CcSEcCtD
Imatinib—ABL1—connective tissue—Graves' disease	0.0019	0.013	CbGeAlD
Imatinib—Paraesthesia—Methimazole—Graves' disease	0.00189	0.00708	CcSEcCtD
Imatinib—Somnolence—Methimazole—Graves' disease	0.00187	0.00701	CcSEcCtD
Imatinib—Myalgia—Propylthiouracil—Graves' disease	0.00187	0.00699	CcSEcCtD
Imatinib—Arthralgia—Propylthiouracil—Graves' disease	0.00187	0.00699	CcSEcCtD
Imatinib—Dyspepsia—Methimazole—Graves' disease	0.00185	0.00694	CcSEcCtD
Imatinib—CSF1R—pituitary gland—Graves' disease	0.00185	0.0127	CbGeAlD
Imatinib—CSF1R—adipose tissue—Graves' disease	0.00184	0.0126	CbGeAlD
Imatinib—NQO2—thyroid gland—Graves' disease	0.00181	0.0125	CbGeAlD
Imatinib—PDGFRA—thyroid gland—Graves' disease	0.00181	0.0124	CbGeAlD
Imatinib—Oedema—Propylthiouracil—Graves' disease	0.00179	0.0067	CcSEcCtD
Imatinib—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00175	0.00656	CcSEcCtD
Imatinib—SLC47A1—pituitary gland—Graves' disease	0.00169	0.0116	CbGeAlD
Imatinib—SLC47A1—adipose tissue—Graves' disease	0.00168	0.0115	CbGeAlD
Imatinib—KIT—pituitary gland—Graves' disease	0.00168	0.0115	CbGeAlD
Imatinib—KIT—adipose tissue—Graves' disease	0.00167	0.0115	CbGeAlD
Imatinib—Urticaria—Methimazole—Graves' disease	0.00167	0.00626	CcSEcCtD
Imatinib—Body temperature increased—Methimazole—Graves' disease	0.00166	0.00623	CcSEcCtD
Imatinib—PDGFRB—pituitary gland—Graves' disease	0.00164	0.0113	CbGeAlD
Imatinib—PDGFRB—adipose tissue—Graves' disease	0.00163	0.0112	CbGeAlD
Imatinib—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00163	0.0061	CcSEcCtD
Imatinib—Paraesthesia—Propylthiouracil—Graves' disease	0.00161	0.00602	CcSEcCtD
Imatinib—CSF1R—thyroid gland—Graves' disease	0.00159	0.0109	CbGeAlD
Imatinib—Somnolence—Propylthiouracil—Graves' disease	0.00159	0.00596	CcSEcCtD
Imatinib—Dyspepsia—Propylthiouracil—Graves' disease	0.00157	0.0059	CcSEcCtD
Imatinib—CA1—adipose tissue—Graves' disease	0.00153	0.0105	CbGeAlD
Imatinib—Pruritus—Methimazole—Graves' disease	0.00149	0.00558	CcSEcCtD
Imatinib—ABL1—pituitary gland—Graves' disease	0.00146	0.01	CbGeAlD
Imatinib—SLC47A1—thyroid gland—Graves' disease	0.00146	0.00999	CbGeAlD
Imatinib—ABL1—adipose tissue—Graves' disease	0.00146	0.00999	CbGeAlD
Imatinib—KIT—thyroid gland—Graves' disease	0.00145	0.00993	CbGeAlD
Imatinib—Urticaria—Propylthiouracil—Graves' disease	0.00142	0.00532	CcSEcCtD
Imatinib—Body temperature increased—Propylthiouracil—Graves' disease	0.00141	0.0053	CcSEcCtD
Imatinib—PDGFRB—thyroid gland—Graves' disease	0.00141	0.0097	CbGeAlD
Imatinib—SLC22A1—adipose tissue—Graves' disease	0.0014	0.00963	CbGeAlD
Imatinib—CA2—eye—Graves' disease	0.00134	0.0092	CbGeAlD
Imatinib—Vomiting—Methimazole—Graves' disease	0.00134	0.00501	CcSEcCtD
Imatinib—Rash—Methimazole—Graves' disease	0.00133	0.00497	CcSEcCtD
Imatinib—Dermatitis—Methimazole—Graves' disease	0.00132	0.00496	CcSEcCtD
Imatinib—Headache—Methimazole—Graves' disease	0.00132	0.00494	CcSEcCtD
Imatinib—CA2—connective tissue—Graves' disease	0.00129	0.00887	CbGeAlD
Imatinib—Pruritus—Propylthiouracil—Graves' disease	0.00127	0.00474	CcSEcCtD
Imatinib—ABL1—thyroid gland—Graves' disease	0.00126	0.00865	CbGeAlD
Imatinib—Nausea—Methimazole—Graves' disease	0.00125	0.00468	CcSEcCtD
Imatinib—Vomiting—Propylthiouracil—Graves' disease	0.00114	0.00426	CcSEcCtD
Imatinib—Rash—Propylthiouracil—Graves' disease	0.00113	0.00422	CcSEcCtD
Imatinib—Dermatitis—Propylthiouracil—Graves' disease	0.00113	0.00422	CcSEcCtD
Imatinib—Headache—Propylthiouracil—Graves' disease	0.00112	0.0042	CcSEcCtD
Imatinib—Nausea—Propylthiouracil—Graves' disease	0.00106	0.00398	CcSEcCtD
Imatinib—PTGS1—connective tissue—Graves' disease	0.000998	0.00685	CbGeAlD
Imatinib—CA2—pituitary gland—Graves' disease	0.000995	0.00683	CbGeAlD
Imatinib—CA2—adipose tissue—Graves' disease	0.000991	0.0068	CbGeAlD
Imatinib—ABCG2—pituitary gland—Graves' disease	0.000922	0.00633	CbGeAlD
Imatinib—ABCG2—adipose tissue—Graves' disease	0.000918	0.0063	CbGeAlD
Imatinib—CA2—thyroid gland—Graves' disease	0.000858	0.00589	CbGeAlD
Imatinib—CYP3A5—adipose tissue—Graves' disease	0.000852	0.00585	CbGeAlD
Imatinib—ABCG2—thyroid gland—Graves' disease	0.000795	0.00545	CbGeAlD
Imatinib—PTGS1—pituitary gland—Graves' disease	0.000769	0.00528	CbGeAlD
Imatinib—PTGS1—adipose tissue—Graves' disease	0.000766	0.00525	CbGeAlD
Imatinib—CYP1A2—thyroid gland—Graves' disease	0.000765	0.00525	CbGeAlD
Imatinib—PTGS1—thyroid gland—Graves' disease	0.000663	0.00455	CbGeAlD
Imatinib—ABCB1—pituitary gland—Graves' disease	0.000454	0.00312	CbGeAlD
Imatinib—ABCB1—adipose tissue—Graves' disease	0.000453	0.00311	CbGeAlD
Imatinib—ABCB1—thyroid gland—Graves' disease	0.000392	0.00269	CbGeAlD
Imatinib—KIT—Innate Immune System—IFIH1—Graves' disease	0.00011	0.00211	CbGpPWpGaD
Imatinib—PTGS1—Selenium Micronutrient Network—IFNG—Graves' disease	0.000109	0.00209	CbGpPWpGaD
Imatinib—SLC22A2—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000109	0.00209	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—HLA-B—Graves' disease	0.000108	0.00208	CbGpPWpGaD
Imatinib—ALB—Vitamin B12 Metabolism—IFNG—Graves' disease	0.000108	0.00208	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—HLA-B—Graves' disease	0.000108	0.00208	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—FASLG—Graves' disease	0.000106	0.00203	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HLA-E—Graves' disease	0.000105	0.00202	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—IFIH1—Graves' disease	0.000104	0.00199	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—FAS—Graves' disease	0.000102	0.00196	CbGpPWpGaD
Imatinib—SLC22A1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000101	0.00195	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—IL2RA—Graves' disease	0.000101	0.00195	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—HLA-A—Graves' disease	0.0001	0.00192	CbGpPWpGaD
Imatinib—CA2—Metabolism—B3GNT2—Graves' disease	9.86e-05	0.0019	CbGpPWpGaD
Imatinib—PTGS1—Selenium Micronutrient Network—IL1B—Graves' disease	9.72e-05	0.00187	CbGpPWpGaD
Imatinib—ALB—Vitamin B12 Metabolism—IL1B—Graves' disease	9.65e-05	0.00186	CbGpPWpGaD
Imatinib—CA1—Metabolism—B3GNT2—Graves' disease	9.46e-05	0.00182	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—IFIH1—Graves' disease	9.35e-05	0.0018	CbGpPWpGaD
Imatinib—ALB—Selenium Micronutrient Network—ICAM1—Graves' disease	9.19e-05	0.00177	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	9.15e-05	0.00176	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—IFIH1—Graves' disease	9.11e-05	0.00175	CbGpPWpGaD
Imatinib—NTRK1—MAPK Signaling Pathway—TNF—Graves' disease	9.01e-05	0.00173	CbGpPWpGaD
Imatinib—LCK—Signaling by Interleukins—IL1B—Graves' disease	8.86e-05	0.0017	CbGpPWpGaD
Imatinib—ALB—Folate Metabolism—IFNG—Graves' disease	8.81e-05	0.00169	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—HLA-E—Graves' disease	8.62e-05	0.00166	CbGpPWpGaD
Imatinib—LCK—HIV Infection—HLA-A—Graves' disease	8.55e-05	0.00164	CbGpPWpGaD
Imatinib—LCK—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	8.49e-05	0.00163	CbGpPWpGaD
Imatinib—LCK—Host Interactions of HIV factors—CD4—Graves' disease	8.48e-05	0.00163	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HLA-DQB1—Graves' disease	8.35e-05	0.0016	CbGpPWpGaD
Imatinib—CA9—Metabolism—B3GNT2—Graves' disease	8.31e-05	0.0016	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HLA-E—Graves' disease	8.28e-05	0.00159	CbGpPWpGaD
Imatinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	8.22e-05	0.00158	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—HLA-E—Graves' disease	8.16e-05	0.00157	CbGpPWpGaD
Imatinib—NTRK1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	8.13e-05	0.00156	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—CD40—Graves' disease	8.09e-05	0.00156	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—CTLA4—Graves' disease	7.98e-05	0.00153	CbGpPWpGaD
Imatinib—ALB—Folate Metabolism—IL1B—Graves' disease	7.86e-05	0.00151	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HLA-E—Graves' disease	7.84e-05	0.00151	CbGpPWpGaD
Imatinib—PDGFRB—MAPK Signaling Pathway—IL1B—Graves' disease	7.75e-05	0.00149	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—GC—Graves' disease	7.68e-05	0.00148	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—CD40—Graves' disease	7.66e-05	0.00147	CbGpPWpGaD
Imatinib—KIT—Disease—B3GNT2—Graves' disease	7.57e-05	0.00145	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—CTLA4—Graves' disease	7.55e-05	0.00145	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—IFIH1—Graves' disease	7.5e-05	0.00144	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HLA-B—Graves' disease	7.5e-05	0.00144	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—HLA-E—Graves' disease	7.35e-05	0.00141	CbGpPWpGaD
Imatinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	7.33e-05	0.00141	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—HLA-E—Graves' disease	7.17e-05	0.00138	CbGpPWpGaD
Imatinib—PDGFRA—Disease—B3GNT2—Graves' disease	7.16e-05	0.00138	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HLA-E—Graves' disease	7.06e-05	0.00136	CbGpPWpGaD
Imatinib—PTGS1—Selenium Micronutrient Network—TNF—Graves' disease	7.05e-05	0.00135	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL2RA—Graves' disease	7.03e-05	0.00135	CbGpPWpGaD
Imatinib—ALB—Vitamin B12 Metabolism—TNF—Graves' disease	7.01e-05	0.00135	CbGpPWpGaD
Imatinib—ALB—Selenium Micronutrient Network—IFNG—Graves' disease	7e-05	0.00134	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HLA-A—Graves' disease	6.95e-05	0.00134	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD40—Graves' disease	6.9e-05	0.00133	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—GC—Graves' disease	6.89e-05	0.00133	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CTLA4—Graves' disease	6.8e-05	0.00131	CbGpPWpGaD
Imatinib—ALB—Transmembrane transport of small molecules—GABRA3—Graves' disease	6.79e-05	0.0013	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—IFNG—Graves' disease	6.68e-05	0.00128	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HLA-DQB1—Graves' disease	6.57e-05	0.00126	CbGpPWpGaD
Imatinib—ABL2—Developmental Biology—TNF—Graves' disease	6.55e-05	0.00126	CbGpPWpGaD
Imatinib—PDGFRB—Disease—B3GNT2—Graves' disease	6.45e-05	0.00124	CbGpPWpGaD
Imatinib—KIT—Immune System—IFIH1—Graves' disease	6.38e-05	0.00123	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	6.35e-05	0.00122	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—GC—Graves' disease	6.29e-05	0.00121	CbGpPWpGaD
Imatinib—ALB—Selenium Micronutrient Network—IL1B—Graves' disease	6.24e-05	0.0012	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HLA-DQB1—Graves' disease	6.22e-05	0.0012	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—HLA-B—Graves' disease	6.15e-05	0.00118	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—CD8A—Graves' disease	6.13e-05	0.00118	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—ICAM1—Graves' disease	6.09e-05	0.00117	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IFIH1—Graves' disease	6.04e-05	0.00116	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TSHR—Graves' disease	5.99e-05	0.00115	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—IL1B—Graves' disease	5.96e-05	0.00115	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	5.95e-05	0.00114	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HLA-E—Graves' disease	5.9e-05	0.00113	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HLA-B—Graves' disease	5.9e-05	0.00113	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—HLA-B—Graves' disease	5.82e-05	0.00112	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—CD8A—Graves' disease	5.81e-05	0.00112	CbGpPWpGaD
Imatinib—ALB—Folate Metabolism—TNF—Graves' disease	5.7e-05	0.0011	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HLA-E—Graves' disease	5.67e-05	0.00109	CbGpPWpGaD
Imatinib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	5.64e-05	0.00108	CbGpPWpGaD
Imatinib—PDGFRB—MAPK Signaling Pathway—TNF—Graves' disease	5.63e-05	0.00108	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HLA-DQB1—Graves' disease	5.6e-05	0.00108	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HLA-B—Graves' disease	5.59e-05	0.00107	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—GC—Graves' disease	5.54e-05	0.00107	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD40—Graves' disease	5.54e-05	0.00106	CbGpPWpGaD
Imatinib—LCK—HIV Infection—CD4—Graves' disease	5.51e-05	0.00106	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—GC—Graves' disease	5.49e-05	0.00106	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—GC—Graves' disease	5.49e-05	0.00105	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HLA-A—Graves' disease	5.47e-05	0.00105	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CTLA4—Graves' disease	5.46e-05	0.00105	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IFIH1—Graves' disease	5.44e-05	0.00105	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	5.37e-05	0.00103	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—GC—Graves' disease	5.33e-05	0.00102	CbGpPWpGaD
Imatinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	5.32e-05	0.00102	CbGpPWpGaD
Imatinib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	5.32e-05	0.00102	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—IL2RA—Graves' disease	5.32e-05	0.00102	CbGpPWpGaD
Imatinib—ABL1—Immune System—IFIH1—Graves' disease	5.31e-05	0.00102	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—HLA-B—Graves' disease	5.24e-05	0.00101	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD8A—Graves' disease	5.23e-05	0.00101	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	5.21e-05	0.001	CbGpPWpGaD
Imatinib—LCK—Disease—B3GNT2—Graves' disease	5.18e-05	0.000995	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HLA-A—Graves' disease	5.18e-05	0.000995	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GC—Graves' disease	5.11e-05	0.000983	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—HLA-B—Graves' disease	5.11e-05	0.000981	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	5.08e-05	0.000976	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HLA-B—Graves' disease	5.03e-05	0.000967	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	5.03e-05	0.000966	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-E—Graves' disease	5.02e-05	0.000965	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HLA-DRB1—Graves' disease	5e-05	0.00096	CbGpPWpGaD
Imatinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	4.95e-05	0.000951	CbGpPWpGaD
Imatinib—KIT—Immune System—CD40—Graves' disease	4.91e-05	0.000944	CbGpPWpGaD
Imatinib—KIT—Immune System—CTLA4—Graves' disease	4.84e-05	0.00093	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—ICAM1—Graves' disease	4.79e-05	0.000921	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-E—Graves' disease	4.75e-05	0.000914	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HLA-DRB1—Graves' disease	4.73e-05	0.000909	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HLA-A—Graves' disease	4.66e-05	0.000896	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD40—Graves' disease	4.65e-05	0.000893	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IFNG—Graves' disease	4.64e-05	0.000891	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CTLA4—Graves' disease	4.58e-05	0.00088	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—ICAM1—Graves' disease	4.54e-05	0.000872	CbGpPWpGaD
Imatinib—ALB—Selenium Micronutrient Network—TNF—Graves' disease	4.53e-05	0.00087	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HLA-DQB1—Graves' disease	4.5e-05	0.000864	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TSHR—Graves' disease	4.39e-05	0.000844	CbGpPWpGaD
Imatinib—LCK—Hemostasis—IL2RA—Graves' disease	4.38e-05	0.000841	CbGpPWpGaD
Imatinib—LCK—Immune System—IFIH1—Graves' disease	4.37e-05	0.00084	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—TNF—Graves' disease	4.33e-05	0.000831	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-E—Graves' disease	4.28e-05	0.000823	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HLA-DRB1—Graves' disease	4.26e-05	0.000819	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HLA-B—Graves' disease	4.21e-05	0.000808	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—B3GNT2—Graves' disease	4.2e-05	0.000807	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD8A—Graves' disease	4.2e-05	0.000807	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD40—Graves' disease	4.19e-05	0.000805	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-E—Graves' disease	4.17e-05	0.000802	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—B3GNT2—Graves' disease	4.16e-05	0.0008	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—B3GNT2—Graves' disease	4.16e-05	0.000799	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TSHR—Graves' disease	4.16e-05	0.000799	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL1B—Graves' disease	4.14e-05	0.000795	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CTLA4—Graves' disease	4.13e-05	0.000793	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—ICAM1—Graves' disease	4.09e-05	0.000786	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD40—Graves' disease	4.08e-05	0.000784	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HLA-B—Graves' disease	4.04e-05	0.000776	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—B3GNT2—Graves' disease	4.04e-05	0.000776	CbGpPWpGaD
Imatinib—ABL1—Immune System—CTLA4—Graves' disease	4.02e-05	0.000773	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-DQB1—Graves' disease	3.98e-05	0.000766	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GC—Graves' disease	3.97e-05	0.000763	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—B3GNT2—Graves' disease	3.88e-05	0.000745	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CXCL10—Graves' disease	3.87e-05	0.000744	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-DQB1—Graves' disease	3.77e-05	0.000725	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TSHR—Graves' disease	3.74e-05	0.00072	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HLA-A—Graves' disease	3.74e-05	0.000719	CbGpPWpGaD
Imatinib—KIT—Immune System—CD8A—Graves' disease	3.72e-05	0.000715	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—CD4—Graves' disease	3.67e-05	0.000705	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-B—Graves' disease	3.58e-05	0.000688	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—CD4—Graves' disease	3.52e-05	0.000677	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD8A—Graves' disease	3.52e-05	0.000677	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—CD4—Graves' disease	3.47e-05	0.000667	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-E—Graves' disease	3.44e-05	0.000661	CbGpPWpGaD
Imatinib—ALB—Metabolism—GC—Graves' disease	3.42e-05	0.000657	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HLA-DRB1—Graves' disease	3.42e-05	0.000657	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-DQB1—Graves' disease	3.4e-05	0.000653	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-B—Graves' disease	3.39e-05	0.000651	CbGpPWpGaD
Imatinib—LCK—Immune System—CD40—Graves' disease	3.36e-05	0.000646	CbGpPWpGaD
Imatinib—KIT—Immune System—IL2RA—Graves' disease	3.35e-05	0.000645	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—CD4—Graves' disease	3.34e-05	0.000641	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-A—Graves' disease	3.32e-05	0.000637	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-DQB1—Graves' disease	3.31e-05	0.000636	CbGpPWpGaD
Imatinib—LCK—Immune System—CTLA4—Graves' disease	3.31e-05	0.000636	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—ICAM1—Graves' disease	3.28e-05	0.000631	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL2RA—Graves' disease	3.17e-05	0.00061	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD8A—Graves' disease	3.17e-05	0.00061	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-A—Graves' disease	3.14e-05	0.000603	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—CD4—Graves' disease	3.13e-05	0.000601	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD8A—Graves' disease	3.09e-05	0.000594	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GC—Graves' disease	3.07e-05	0.00059	CbGpPWpGaD
Imatinib—KIT—Disease—HLA-A—Graves' disease	3.06e-05	0.000588	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-B—Graves' disease	3.05e-05	0.000587	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—CD4—Graves' disease	3.05e-05	0.000586	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-DRB1—Graves' disease	3.03e-05	0.000582	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—B3GNT2—Graves' disease	3.01e-05	0.000578	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TSHR—Graves' disease	3e-05	0.000577	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD4—Graves' disease	3e-05	0.000577	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GC—Graves' disease	3e-05	0.000576	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-B—Graves' disease	2.97e-05	0.000572	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL2RA—Graves' disease	2.96e-05	0.000569	CbGpPWpGaD
Imatinib—KIT—Immune System—ICAM1—Graves' disease	2.91e-05	0.000559	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HLA-A—Graves' disease	2.9e-05	0.000557	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-DRB1—Graves' disease	2.87e-05	0.000551	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL2RA—Graves' disease	2.86e-05	0.00055	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CXCL10—Graves' disease	2.84e-05	0.000545	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-A—Graves' disease	2.83e-05	0.000544	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GC—Graves' disease	2.82e-05	0.000543	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GC—Graves' disease	2.8e-05	0.000538	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL2RA—Graves' disease	2.79e-05	0.000536	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-A—Graves' disease	2.76e-05	0.00053	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—ICAM1—Graves' disease	2.75e-05	0.000529	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-DQB1—Graves' disease	2.73e-05	0.000524	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CXCL10—Graves' disease	2.69e-05	0.000516	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IL2RA—Graves' disease	2.62e-05	0.000503	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HLA-A—Graves' disease	2.61e-05	0.000502	CbGpPWpGaD
Imatinib—ALB—Metabolism—B3GNT2—Graves' disease	2.59e-05	0.000498	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-DRB1—Graves' disease	2.58e-05	0.000497	CbGpPWpGaD
Imatinib—LCK—Immune System—CD8A—Graves' disease	2.55e-05	0.000489	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-DRB1—Graves' disease	2.52e-05	0.000484	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CD4—Graves' disease	2.51e-05	0.000483	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—ICAM1—Graves' disease	2.48e-05	0.000477	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-B—Graves' disease	2.45e-05	0.000471	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL10—Graves' disease	2.42e-05	0.000465	CbGpPWpGaD
Imatinib—ABL1—Immune System—ICAM1—Graves' disease	2.42e-05	0.000464	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD4—Graves' disease	2.41e-05	0.000463	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GC—Graves' disease	2.39e-05	0.00046	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—B3GNT2—Graves' disease	2.33e-05	0.000447	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TNF—Graves' disease	2.31e-05	0.000445	CbGpPWpGaD
Imatinib—LCK—Immune System—IL2RA—Graves' disease	2.3e-05	0.000441	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—B3GNT2—Graves' disease	2.27e-05	0.000437	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-A—Graves' disease	2.27e-05	0.000436	CbGpPWpGaD
Imatinib—KIT—Immune System—IFNG—Graves' disease	2.21e-05	0.000425	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL2RA—Graves' disease	2.17e-05	0.000417	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—B3GNT2—Graves' disease	2.14e-05	0.000411	CbGpPWpGaD
Imatinib—KIT—Immune System—CD4—Graves' disease	2.14e-05	0.000411	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	2.13e-05	0.00041	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—B3GNT2—Graves' disease	2.12e-05	0.000408	CbGpPWpGaD
Imatinib—LCK—Disease—HLA-A—Graves' disease	2.1e-05	0.000403	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IFNG—Graves' disease	2.09e-05	0.000403	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-DRB1—Graves' disease	2.07e-05	0.000398	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2RA—Graves' disease	2.05e-05	0.000394	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD4—Graves' disease	2.02e-05	0.000389	CbGpPWpGaD
Imatinib—LCK—Immune System—ICAM1—Graves' disease	1.99e-05	0.000382	CbGpPWpGaD
Imatinib—KIT—Immune System—IL1B—Graves' disease	1.97e-05	0.000379	CbGpPWpGaD
Imatinib—KIT—Disease—CD4—Graves' disease	1.97e-05	0.000379	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL10—Graves' disease	1.94e-05	0.000373	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IFNG—Graves' disease	1.89e-05	0.000363	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL1B—Graves' disease	1.87e-05	0.000359	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CD4—Graves' disease	1.87e-05	0.000359	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2RA—Graves' disease	1.85e-05	0.000355	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GC—Graves' disease	1.85e-05	0.000355	CbGpPWpGaD
Imatinib—ABL1—Immune System—IFNG—Graves' disease	1.84e-05	0.000353	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD4—Graves' disease	1.82e-05	0.00035	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—B3GNT2—Graves' disease	1.81e-05	0.000348	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD4—Graves' disease	1.78e-05	0.000341	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL1B—Graves' disease	1.68e-05	0.000323	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CD4—Graves' disease	1.68e-05	0.000323	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL1B—Graves' disease	1.64e-05	0.000315	CbGpPWpGaD
Imatinib—LCK—Immune System—IFNG—Graves' disease	1.51e-05	0.000291	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2RA—Graves' disease	1.48e-05	0.000285	CbGpPWpGaD
Imatinib—LCK—Immune System—CD4—Graves' disease	1.46e-05	0.000281	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—B3GNT2—Graves' disease	1.4e-05	0.000269	CbGpPWpGaD
Imatinib—LCK—Immune System—IL1B—Graves' disease	1.35e-05	0.00026	CbGpPWpGaD
Imatinib—LCK—Disease—CD4—Graves' disease	1.35e-05	0.00026	CbGpPWpGaD
